Literature DB >> 11205254

NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).

J E Pawlowski1, A Nesterov, R I Scheinman, T R Johnson, A S Kraft.   

Abstract

BACKGROUND: Immune cells express TNF-related apoptosis-inducing ligand (TRAIL) and may play an important role in controlling the growth of renal cancer. For this reason we examined the potential cytotoxic and intracellular signaling effects of TRAIL on several renal cancer cell (RCC) lines.
METHODS: Cytotoxicity was determined using an MTS tetrazolium based assay. Death receptor expression was measured by reverse-transcription polymerase chain reaction. Immunoblot analysis was used to measure cFLIP, caspase-8 and phosphorylated JNK and p38. Activation of NF-kappa B was determined by electrophoretic mobility shift assays.
RESULTS: Two RCC lines were highly sensitive to TRAIL-induced cell death, two were of intermediate sensitivity, and two were insensitive. Sensitivity to TRAIL-stimulated apoptosis did not correlate with expression of death receptors, decoy receptors, or expression of the caspase-8-inhibitory protein cFLIP. Neither activation or inhibition of the NF-kappa B signal transduction pathway protected sensitive cells from TRAIL-induced cell death.
CONCLUSIONS: NF-kappa B, although stimulated in these cell lines, does not play a role in the sensitivity of RCC to TRAIL and could play other functions in TRAIL signaling.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205254

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.

Authors:  Alan D Brooks; Kristen M Jacobsen; Wenqing Li; Anil Shanker; Thomas J Sayers
Journal:  Mol Cancer Res       Date:  2010-05-04       Impact factor: 5.852

2.  TLR4 activates NF-κB in human ovarian granulosa tumor cells.

Authors:  Dori C Woods; Yvonne A R White; Caroline Dau; A L Johnson
Journal:  Biochem Biophys Res Commun       Date:  2011-05-17       Impact factor: 3.575

3.  Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.

Authors:  Jee-Eun Kim; Dong-Hoon Jin; Wang Jae Lee; Daeyoung Hur; T-C Wu; Daejin Kim
Journal:  Pharmacol Res       Date:  2013-02-18       Impact factor: 7.658

4.  Up-regulation of the DR5 expression by proteasome inhibitor MG132 augments TRAIL-induced apoptosis in soft tissue sarcoma cell lines.

Authors:  Hee-Jeong Cheong; Kyu Sang Lee; In Sook Woo; Jong-Ho Won; Jae Ho Byun
Journal:  Cancer Res Treat       Date:  2011-06-30       Impact factor: 4.679

5.  Pathway analysis of kidney cancer using proteomics and metabolic profiling.

Authors:  Bertrand Perroud; Jinoo Lee; Nelly Valkova; Amy Dhirapong; Pei-Yin Lin; Oliver Fiehn; Dietmar Kültz; Robert H Weiss
Journal:  Mol Cancer       Date:  2006-11-24       Impact factor: 27.401

6.  Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage.

Authors:  U Ramp; E Caliskan; C Mahotka; A Krieg; S Heikaus; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.